주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
IDWeek 2024
16 Oct 019 Oct, 2024, United States
High-dose VE303 reduces ARG levels in individuals with CDI
2024-11-28
Treatment with high-dose VE303, a defined bacterial consortium composed of eight strains of commensal Clostridia, was associated with a significant reduction in antibiotic resistance genes (ARGs) among individuals with Clostridioides difficile infection (CDI), according to the phase II CONSORTIUM* study presented at IDWeek 2024.
Maternal faecal microbiota transfer helps address gut dysbiosis in C-section?delivered infants
2024-11-28
Transplantation of maternal faecal microbiota may safely correct gut microbiota imbalance in infants born via caesarean section (C-section), according to the results of the SECFLOR* trial.
MVA-BN vax shows favourable safety, tolerability in adolescents in phase II study
2024-11-28
Interim data from a phase II trial demonstrate the safety and tolerability of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in adolescents. MVA-BN is a live attenuated, non-replicating orthopoxvirus vaccine licensed in the US for smallpox and mpox prevention.
Nirmatrelvir/ritonavir for COVID-19 in children passes safety test
2024-11-28
Treatment of symptomatic COVID-19 with nirmatrelvir/ritonavir in children at least 6 years of age who are at risk of progression to severe disease appears to be safe and well-tolerated, with pharmacokinetic data from the open-label phase 2/3 EPIC-Peds* study indicating suitable dosing regimens for two distinct weight categories of this population.
Norovirus vaccine one step closer to reality
2024-11-28
A single injection of mRNA-1403, a multivalent norovirus mRNA vaccine, induces a robust serum histo-blood group antigen (HBGA)-blocking antibody response across all dose levels in adults, as shown by interim results of an ongoing phase I/II trial presented at IDWeek 2024. Comparable findings have been observed with serum virus-like particle (VLP)-binding antibody responses.
Novel device offers OTC solution for prompt STI testing
2024-11-28
The Visby Medical Women’s Sexual Health Test ? a single-use PCR platform that combines sample preparation, nucleic acid amplification, and detection into an integrated device ? offers an over-the-counter solution for the detection of DNA from pathogens such as Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV).
Novel islatravir + lenacapavir combo maintains high viral suppression rates
2024-11-28
Once-weekly treatment with islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor, led to sustained high rates of viral suppression at week 48 among people with HIV, according to the secondary endpoint results of a phase II study presented at IDWeek 2024.
Pooled saliva tests for cCMV infection feasible, cost-effective
2024-11-28
Pooled saliva tests for congenital cytomegalovirus (cCMV) infection are both accurate and cost-efficient, potentially transforming the implementation of universal cCMV screening, suggests a study presented at IDWeek 2024.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
